Department of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
Malar J. 2010 May 24;9:136. doi: 10.1186/1475-2875-9-136.
There is renewed acknowledgement that targeting gametocytes is essential for malaria control and elimination efforts. Simple mathematical models were fitted to data from clinical trials in order to determine the mean gametocyte circulation time and duration of gametocyte carriage in treated malaria patients.
Data were used from clinical trials from East Africa. The first trial compared non-artemisinin combination therapy (non-ACT: sulphadoxine-pyrimethamine (SP) plus amodiaquine) and artemisinin-based combination therapy (ACT: SP plus artesunate (AS) or artemether-lumefantrine). The second trial compared ACT (SP+AS) with ACT in combination with a single dose of primaquine (ACT-PQ: SP+AS+PQ). Mature gametocytes were quantified in peripheral blood samples by nucleic acid sequence based amplification. A simple deterministic compartmental model was fitted to gametocyte densities to estimate the circulation time per gametocyte; a similar model was fitted to gametocyte prevalences to estimate the duration of gametocyte carriage after efficacious treatment.
The mean circulation time of gametocytes was 4.6-6.5 days. After non-ACT treatment, patients were estimated to carry gametocytes for an average of 55 days (95% CI 28.7 - 107.7). ACT reduced the duration of gametocyte carriage fourfold to 13.4 days (95% CI 10.2-17.5). Addition of PQ to ACT resulted in a further fourfold reduction of the duration of gametocyte carriage.
These findings confirm previous estimates of the circulation time of gametocytes, but indicate a much longer duration of (low density) gametocyte carriage after apparently successful clearance of asexual parasites. ACT shortened the period of gametocyte carriage considerably, and had the most pronounced effect on mature gametocytes when combined with PQ.
人们重新认识到,针对配子体是控制和消除疟疾努力的关键。为了确定经治疗疟疾患者的配子体循环时间和携带时间,我们对来自东非临床试验的数据进行了简单的数学模型拟合。
使用了来自东非临床试验的数据。第一项试验比较了非青蒿素类联合疗法(非 ACT:磺胺多辛-乙胺嘧啶(SP)加阿莫地喹)和基于青蒿素的联合疗法(ACT:SP 加青蒿琥酯(AS)或青蒿素-咯萘啶)。第二项试验比较了 ACT(SP+AS)与 ACT 加一剂伯氨喹(ACT-PQ:SP+AS+PQ)。通过核酸序列扩增技术在外周血样本中定量成熟配子体。我们使用简单的确定性房室模型拟合配子体密度,以估计每个配子体的循环时间;使用类似的模型拟合配子体流行率,以估计有效治疗后配子体携带的持续时间。
配子体的平均循环时间为 4.6-6.5 天。非 ACT 治疗后,患者携带配子体的平均时间估计为 55 天(95%CI 28.7-107.7)。ACT 将配子体携带时间减少了四倍,至 13.4 天(95%CI 10.2-17.5)。将 PQ 添加到 ACT 中可进一步将配子体携带时间减少四倍。
这些发现证实了以前对配子体循环时间的估计,但表明在明显清除无性寄生虫后,配子体的(低密度)携带时间要长得多。ACT 大大缩短了配子体携带期,当与 PQ 联合使用时,对成熟配子体的影响最为显著。